While Amgen Sees Success For Two Growth Drivers, Headwinds Remain

Breakthrough Drugs Sotorasib, Tezepelumab Edge Closer To Market

 
• By Mandy Jackson
Amgen sign at biopharmaceutical company campus in Silicon Valley, biotech company headquartered in Thousand Oaks - South San Francisco, CA, USA - 2020
Amgen's sotorasib is filed with the US FDA; tezepelumab is being prepared for filings • Source: Shutterstock

More from Business

More from Scrip